Eisai/Janssen Aciphex Sales Closing In On $250 Mil. 13 Months After Launch
Executive Summary
Janssen/Eisai's proton pump inhibitor Aciphex (rabeprazole) is closing in on $250 mil. in sales after 13 months on the market, Eisai U.S. Chairman Soichi Matsuno indicated Oct. 3 at a UBS Warburg Global Life Sciences Conference in New York City.